|
Activity Number:
|
424
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 9, 2006 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305393 |
|
Title:
|
What Is a Suitable Definition of Study Information in Longitudinal Clinical Trials?
|
|
Author(s):
|
Guoguang Ma*+ and Michael Nessly
|
|
Companies:
|
Merck & Co., Inc. and Merck Research Laboratories
|
|
Address:
|
10 Sentry Parkway, Blue Bell, PA, 19422,
|
|
Keywords:
|
study information ; longitudinal trial
|
|
Abstract:
|
The total study information can be expressed either as the total number of patients or the total number of events in one sample problem. The repeated measurement setting, however, does not fit directly into this framework. The inverse of the variance of the estimated difference obtained at the planned end of the study is a logical choice. But it is dependent on the values of some unknown parameters. Wu and Lan (1992) introduced a surrogate information expression regarding the total number of measurements to be made as the total information. More recently, Kittelson et al. (2005) calculated the study information as a function of the covariance, the number of subjects, and the amount of follow up on each subject. In this work, we compare these approaches and discuss what could be a suitable definition of study information through simulation studies and a proof-of-concept study.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2006 program |
